Table 2 Stability of differentially capped RNAs in human immature and mature DCs (iDCs and mDCs, respectively)

From: Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

5′ Cap structure

Cells

mRNA half-life (h) (2–8 h after electroporation)

mRNA half-life (h) (24–72 h after electroporation)

Cells

mRNA half-life (h) (2–72 h after electroporation)

No cap

iDCs

1.41±0.02

NA

mDCs

10.36±0.18

ApppG

iDCs

5.98±0.49

14.06±1.43

mDCs

15.30±0.64

GpppG

iDCs

4.82±0.71

24.45±4.40

mDCs

14.64±0.32

m7GpppG/c.t.

iDCs

5.82±1.46

16.10±1.83

mDCs

13.11±0.82

m7Gppppm7G

iDCs

2.37±0.09

19.37±0.34

mDCs

11.88±0.39

ARCA

iDCs

5.47±0.87

15.50±1.57

mDCs

13.63±0.55

β-S-ARCA(D1)

iDCs

8.27±1.15

27.00±2.85

mDCs

13.94±0.82

β-S-ARCA(D2)

iDCs

6.72±1.48

18.09±0.81

mDCs

14.20±0.89

m7GpppG/p.t.

iDCs

6.11±0.33

15.60±7.24

mDCs

13.27±0.28

  1. Abbreviations: ARCA, anti-reverse cap analogs; DCs, dendritic cells; NA, not applicable.
  2. Listed are average values±s.d.
Back to article page